Wilson's Disease

ABSTRACT

Wilson's disease is an autosomal-recessive disorder caused by mutation in the ATP7B gene, with resultant impairment of biliary excretion of copper. Subsequent copper accumulation, first in the liver but ultimately in the brain and other tissues, produces protean clinical manifestations that may include hepatic, neurological, psychiatric, ophthalmological, and other derangements. Genetic testing is impractical because of the multitude of mutations that have been identified, so accurate diagnosis relies on judicious use of a battery of laboratory and other diagnostic tests. Lifelong palliative treatment with a growing stable of medications, or with liver transplantation if needed, can successfully ameliorate or prevent the progressive deterioration and eventual death that would otherwise inevitably ensue. This article discusses the epidemiology, genetics, pathophysiology, clinical features, diagnostic testing, and treatment of Wilson's disease.

KEYWORDS

Ceruloplasmin - copper - Wilson's disease - penicillamine - zinc

REFERENCES

• 1 Walshe J M. History of Wilson's disease: 1912 to 2000.  Mov Disord. 2006;  21 142-147
• 2 Wilson S AK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver.  Brain. 1912;  34 295-507
• 3 Kayser B. Uber einen Fall von angeborener grünlicher Verfärbung der Kornea.  Klin Monatsbl Augenheilkd. 1902;  40 22-25
• 4 Fleischer B. Zwei weiterer Falle von grünlicher Verfärbung der Kornea.  Klin Monatsbl Augenheilkd. 1903;  41 489-491
• 5 Fleischer B. Uber eine der “Pseudosklerose” nahestehende, bisher unbekannte Krankheit (gekennzeichnet durch tremor, psychische storungen, braunliche Pigmentierung bestimmter gewebe, inbesondere auch der Hornhautperipherie, Lebercirrhose).  Dtsch Z Nervenheilkd. 1912;  44 179-201
• 6 Rumpel A. Über das Wesen und die Bedeutung der Leberveränderungen und der Pigmentierunen bei den damit verbundenen Fällen von Psuedosklerose, zugleich ein Beitrag zur Lehre von der Pseudosklerose (Westphal-Strümpell).  Dtsch Z Nervenheilkd. 1913;  49 54-73
• 7 Mandelbrote B M, Stanier M W, Thompson R HS, Thurston M N. Studies on copper metabolism in demyelinating diseases of the central nervous system.  Brain. 1948;  71 212-228
• 8 Cumings J N. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration.  Brain. 1948;  71 410-415
• 9 Scheinberg I H, Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease).  Science. 1952;  116 484-485
• 10 Bearn A G, Kunkel H G. Biochemical abnormalities in Wilson's disease.  J Clin Invest. 1952;  31 616
• 11 Frommer D J. Defective biliary excretion of copper in Wilson's disease.  Gut. 1974;  15 125-129
• 12 Saito T. An assessment of efficiency in potential screening for Wilson's disease.  J Epidemiol Community Health. 1981;  35 274-280
• 13 Scheinberg I H, Sternlieb I. Wilson's Disease. Philadelphia; WB Saunders 1984
• 14 Brewer G J. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston; Kluwer Academic Publishers 2001
• 15 Olivarez L, Caggana M, Pass K A, Ferguson P, Brewer G J. Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach.  Ann Hum Genet. 2001;  65 459-463
• 16 Bull P C, Thomas G R, Rommens J M, Forbes J R, Cox D W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene.  Nat Genet. 1993;  5 327-337
• 17 Petrukhin K, Fischer S G, Piratsu M et al.. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene.  Nat Genet. 1993;  5 338-343
• 18 Yamaguchi Y, Heiny M E, Gitlin J D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease.  Biochem Biophys Res Commun. 1993;  197 271-277
• 19 Petrukhin K, Lutsenko S, Chernov I, Ross B M, Kaplan J H, Gilliam T C. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions.  Hum Mol Genet. 1994;  3 1647-1656
• 20 Cox D W, Prat L, Walshe J M, Heathcote J, Gaffney D. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry.  Hum Mutat. 2005;  26 280-286
• 21 Loudianos G, Lovicu M, Dessi V et al.. Abnormal mRNA splicing resulting from consensus sequence splicing mutations of ATP7B.  Hum Mutat. 2002;  20 260-266
• 22 Gromadzka G, Schmidt H H, Genschel J et al.. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease.  Mov Disord. 2006;  21 245-248
• 23 Vrabelova S, Letocha O, Borsky M, Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease.  Mol Genet Metab. 2005;  86 277-285
• 24 Gromadzka G, Schmidt H H-J, Genschel J et al.. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease.  Clin Genet. 2005;  68 524-532
• 25 Senzolo M, Loreno M, Fagiuoli S et al.. Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins.  Clin Neurol Neurosurg. 2007;  109 71-75
• 26 Grubenbecher S, Stüve O, Hefter H, Korth C. Prion protein gene codon 129 modulates clinical course of neurological Wilson disease.  Neuroreport. 2006;  17 549-552
• 27 Merle U, Stremmel W, Gessner R. Influence of homozygosity for methionine at codon 129 of the human prion gene on the onset of neurological and hepatic symptoms in Wilson disease.  Arch Neurol. 2006;  63 982-985
• 28 Sechi G, Antonio Cocco G A, Errigo A et al.. Three sisters with very-late-onset major depression and parkinsonism.  Parkinsonism Relat Disord. 2006; May 29;  , (Epub ahead of print)
• 29 Hung I H, Suzuki M, Yamaguchi Y, Yuan D S, Klausner R D, Gitlin J D. Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae .  J Biol Chem. 1997;  272 21461-21466
• 30 La Fontaine S, Theophilos M B, Firth S D, Gould R, Parton R G, Mercer J F. Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper ATPase.  Hum Mol Genet. 2001;  10 361-370
• 31 Forbes J R, Cox D W. Copper-dependent trafficking of Wilson disease mutant ATP7B proteins.  Hum Mol Genet. 2000;  9 1927-1935
• 32 Mufti A R, Burstein E, Csomos R A et al.. XIAP is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders.  Mol Cell. 2006;  21 775-785
• 33 Gibbs K, Walshe M. A study of the ceruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups.  Q J Med. 1979;  48 447-463
• 34 Walshe J M. Wilson's disease: the presenting symptoms.  Arch Dis Child. 1962;  37 253-256
• 35 Walshe J M. Wilson's disease (HLD). In: Vinken PJ, Bruyn GW Handbook of Clinical Neurology. Vol. 27. Amsterdam; North Holland Publishing Company 1976: 379-414
• 36 Beyersdorff A, Findeisen A. Morbus Wilson: case report of a two-year-old child as first manifestation.  Scand J Gastroenterol. 2006;  41 496-497
• 37 Gow P J, Smallwood R A, Angus P W, Smith A L, Wall A J, Sewell R B. Diagnosis of Wilson's disease: an experience over three decades.  Gut. 2000;  46 415-419
• 38 Sternlieb I, Scheinberg I H. Chronic hepatitis as a first manifestation of Wilson's disease.  Ann Intern Med. 1972;  76 59-64
• 39 Scott J, Gollan J L, Samourian S, Sherlock S. Wilson's disease presenting as chronic active hepatitis.  Gastroenterology. 1978;  74 645-651
• 40 Schilsky M L, Fink S. Inherited metabolic liver disease.  Curr Opin Gastroenterol. 2006;  22 215-222
• 41 Schilsky M L, Scheinberg I H, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome.  Hepatology. 1994;  19 583-587
• 42 Roche-Sicot J, Benhamou J P. Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease.  Ann Intern Med. 1977;  86 301-303
• 43 Strickland G T, Leu M L. Wilson's disease: clinical and laboratory manifestations in 40 patients.  Medicine. 1975;  54 113-137
• 44 Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis.  Hepatology. 2005;  41 668-670
• 45 Hellman N E, Gitlin J D. Ceruloplasmin metabolism and function.  Annu Rev Nutr. 2002;  22 439-458
• 46 Parker N. Hereditary whispering dysphonia.  J Neurol Neurosurg Psychiatry. 1985;  48 218-224
• 47 Cartwright G E. Diagnosis of treatable Wilson's disease.  N Engl J Med. 1978;  298 1347-1350
• 48 Walshe J M, Yealland M. Wilson's disease: the problem of delayed diagnosis.  J Neurol Neurosurg Psychiatry. 1992;  55 692-696
• 49 Svetel M, Kozic D, Stefanova E, Semnic R, Dragasevic N, Kostic V S. Dystonia in Wilson's disease.  Mov Disord. 2001;  16 719-723
• 50 Barbosa E R, Silveira-Moriyama L, Machado A C, Bacheschi L A, Rosemberg S, Scaff M. Wilson's disease with myoclonus and white matter lesions.  Parkinsonism Relat Disord. 2006; May 30;  (Epub ahead of print) 
• 51 Papapetropoulos S, Singer C. Painless legs moving toes in a patient with Wilson's disease.  Mov Disord. 2006;  21 579-580
• 52 Bhattacharya K, Velickovic M, Schilsky M, Kaufmann H. Autonomic cardiovascular reflexes in Wilson's disease.  Clin Auton Res. 2002;  12 190-192
• 53 Meenakshi-Sundaram S, Taly A B, Kamath V, Arunodaya G R, Rao S, Swamy H S. Autonomic dysfunction in Wilson's disease: a clinical and electrophysiological study.  Clin Auton Res. 2002;  12 185-189
• 54 Dening T R, Berrios G E, Walshe J M. Wilson's disease and epilepsy.  Brain. 1988;  111 1139-1155
• 55 Polychronopoulos P, Argyriou A A, Papapetropoulos S, Gourzis P, Rigas G, Chroni E. Wilson's disease and benign epilepsy of childhood with centrotemporal (rolandic) spikes.  Epilepsy Behav. 2006;  8 438-441
• 56 Kumar S. Wilson's disease presenting as status epilepticus.  Indian Pediatr. 2005;  42 492-493
• 57 Jung K H, Ahn T B, Jeon B S. Wilson disease with an initial manifestation of polyneuropathy.  Arch Neurol. 2005;  62 1628-1631
• 58 Mueller A, Reuner U, Landis B, Kitzler H, Reichmann H, Hummel T. Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction.  Mov Disord. 2006;  21 1311-1316
• 59 Akil M, Schwartz J A, Dutchak D, Yuzbasiyan-Gurkan V, Brewer G J. The psychiatric presentations of Wilson's disease.  J Neuropsychiatry Clin Neurosci. 1991;  3 377-382
• 60 Brewer G J. Behavioral abnormalities in Wilson's disease.  Adv Neurol. 2005;  96 262-274
• 61 Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases.  J Neurol. 1991;  238 281-287
• 62 Dening T R. Psychiatric aspects of Wilson's disease.  Br J Psychiatry. 1985;  147 677-682
• 63 Kaul A, McMahon D. Wilson's disease and offending behavior: a case report.  Med Sci Law. 1993;  33 353-358
• 64 Seniow J, Bak T, Gajda J, Poniatowska R, Czlonkowska A. Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease.  Mov Disord. 2002;  17 1077-1083
• 65 Portala K, Levander S, Westermark K, Ekselius L, von Knorring L. Pattern of neuropsychological deficits in patients with treated Wilson's disease.  Eur Arch Psychiatry Clin Neurosci. 2001;  251 262-268
• 66 Gronlund J, Nanto-Salonen K, Venetoklis J, Holmberg R L, Heinonen A, Stahlberg M R. Poor cognitive development and abdominal pain: Wilson's disease.  Scand J Gastroenterol. 2006;  41 361-364
• 67 Brewer G J. Recognition, diagnosis, and management of Wilson's disease.  Proc Soc Exp Biol Med. 2000;  223 39-46
• 68 Wiebers D O, Hollenhorst R W, Goldstein N P. The ophthalmologic manifestations of Wilson's disease.  Mayo Clin Proc. 1977;  52 409-416
• 69 Johnson R E, Campbell R J. Wilson's disease: electron microscopic, x-ray energy spectroscopic, and atomic absorption spectroscopic studies of corneal copper deposition and distribution.  Lab Invest. 1982;  46 564-569
• 70 Innes J R, Strachan I M, Triger D R. Unilateral Kayser-Fleischer ring.  Br J Ophthalmol. 1986;  70 469-470
• 71 Sussman W, Scheinberg I H. Disappearance of Kayser-Fleischer rings: effects of penicillamine.  Arch Ophthalmol. 1969;  82 738-741
• 72 Ross M E, Jacobson I M, Dienstag D L, Martin J B. Late onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings.  Ann Neurol. 1985;  17 411-413
• 73 Pfeiffer R F. Wilson's disease. In: Watts RL, Koller WC Movement Disorders. Neurologic Principles and Practice. New York; McGraw-Hill Medical Publishers 2004: 779-797
• 74 Siemerling E, Oloff H. Pseudosklerose (Westphal-Strümpell) mit Cornealring (Kayser-Fleischer) und doppelseitiger Scheinkatarakt, die nur bei seitlicher Beleuchtnung sichtbar ist und die der nach Verletzung durch Kupfersplitter entstehenden Katarakt änlich ist.  Klin Wochenschr. 1922;  1 1087-1089
• 75 Cairns J E, Williams H P, Walshe J M. “Sunflower cataract” in Wilson's disease.  Br Med J. 1969;  3 95-96
• 76 Golding D N, Walshe J M. Arthropathy of Wilson's disease: study of clinical and radiological features in 32 patients.  Ann Rheum Dis. 1977;  36 99-111
• 77 Canelas H M, Carvalho N, Scaff M, Vitule A, Barbosa E R, Azevedo E M. Osteoarthropathy of hepatolenticular degeneration.  Acta Neurol Scand. 1978;  57 481-487
• 78 Mindelzun R, Elkin M, Scheinberg I H, Sternlieb I. Skeletal changes in Wilson's disease: a radiological study.  Radiology. 1970;  94 127-132
• 79 Yarze J C, Martin P, Munoz S J, Friedman L S. Wilson's disease: current status.  Am J Med. 1992;  92 643-654
• 80 McIntyre N, Clink H M, Levi A J, Cumings J N, Sherlock S. Hemolytic anemia in Wilson's disease.  N Engl J Med. 1967;  276 439-444
• 81 Sternlieb I. Wilson's disease: indications for liver transplants.  Hepatology. 1984;  4 15S-17S
• 82 Donfrid M, Jankovic G, Strahinja R, Colovic R, Begic-Janeva A, Colovic M. Idiopathic thrombocytopenia associated with Wilson's disease.  Hepatogastroenterology. 1998;  45 1774-1776
• 83 Atanassova P A, Panchovska M S, Tzvetanov P, Chalakova N T, Masaldzhieva R I, Dimitrov B D. Hepatolenticular degeneration combined with primary antiphospholipid syndrome: a case report.  Eur Neurol. 2006;  55 42-43
• 84 Wiebers D O, Wilson D M, McLeod R A, Goldstein N P. Renal stones in Wilson's disease.  Am J Med. 1979;  67 249-254
• 85 Narayanan P, Chetan G, Mahadevan S. Wilson's disease presenting as respiratory failure.  Indian J Pediatr. 2006;  73 99-100
• 86 Leu M L, Strickland G T, Wang C C, Chen T S. Skin pigmentation in Wilson's disease.  JAMA. 1970;  211 1542-1543
• 87 Scheinberg I H, Sternlieb I. Wilson's disease.  Annu Rev Med. 1965;  16 119-134
• 88 Lau J Y, Lai C L, Wu P C, Pan H Y, Lin H J, Todd D. Wilson's disease: 35 years' experience.  Q J Med. 1990;  75 597-605
• 89 Ferenci P, Steindl-Munda P, Vogel W et al.. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease.  Clin Gastroenterol Hepatol. 2005;  3 811-818
• 90 Smallwood R A, Williams H A, Rosenoer V M, Sherlock S. Liver-copper levels in liver disease: studies using neutron activation analysis.  Lancet. 1968;  2 1310-1313
• 91 Benson G D. Hepatic copper accumulation in primary biliary cirrhosis.  Yale J Biol Med. 1979;  52 83-88
• 92 Willeit J, Kiechl S G. Wilson's disease with neurologic impairment but no Kayser-Fleischer rings.  Lancet. 1991;  337 1426
• 93 Oracz G, Klimczak-Slaczka D, Sokolowska-Oracz A et al.. [Prevalence of Kayser-Fleischer ring in patients with Wilson's disease]. [In Polish].  Klin Oczna. 2005;  107 54-56
• 94 Das S K, Ray K. Wilson's disease: an update.  Nat Clin Pract Neurol. 2006;  2 482-493
• 95 Sinha S, Taly A B, Ravishankar S et al.. Wilson's disease: cranial MRI observations and clinical correlation.  Neuroradiology. 2006;  48 613-621
• 96 Walter U, Krolikowski K, Tarnacka B, Benecke R, Czlonkowska A, Dressler D. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease.  Neurology. 2005;  64 1726-1732
• 97 Hartard C, Weisner B, Dieu C, Kunze K. Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration.  J Neurol. 1993;  241 101-107
• 98 Hoogenraad T U. Paradigm shift in the treatment of Wilson's disease: zinc therapy now treatment of choice.  Brain Dev. 2006;  28 141-146
• 99 Walshe J M. Penicillamine, a new oral therapy for Wilson's disease.  Am J Med. 1956;  21 487-495
• 100 Brewer G J, Askari F, Lorincz M T et al.. Treatment of Wilson disease with ammonium tetrathiomolybdate.  Arch Neurol. 2006;  63 521-527
• 101 Walshe J M, Yealland M. Chelation treatment of neurological Wilson's disease.  Q J Med. 1993;  86 197-204
• 102 Brewer G J, Terry C A, Aisen A M, Hill G M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.  Arch Neurol. 1987;  44 490-493
• 103 Prashanth L K, Taly A B, Sinha S et al.. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease.  QJM. 2005;  98 557-563
• 104 Sternlieb I, Scheinberg I H. Penicillamine therapy for hepatolenticular degeneration.  JAMA. 1964;  189 748-754
• 105 Haggstrom G D, Hirschowitz B I, Flint A. Long-term penicillamine therapy for Wilson's disease.  South Med J. 1980;  73 530-531
• 106 Sternlieb I, Fisher M, Scheinberg I H. Penicillamine-induced skin lesions.  J Rheumatol Suppl. 1981;  7 149-154
• 107 Walshe J M. Penicillamine: the treatment of first choice for patients with Wilson's disease.  Mov Disord. 1999;  14 545-550
• 108 Schafer D F, Shaw Jr B W. Fulminant hepatic failure and orthotopic liver transplantation.  Semin Liver Dis. 1989;  9 189-194
• 109 Medici V, Mirante V G, Fassati L R et al.. Liver transplantation for Wilson's disease: the burden of neurological and psychiatric disorders.  Liver Transpl. 2005;  11 1056-1063
• 110 Wang X H, Cheng F, Zhang F et al.. Living-related liver transplantation for Wilson's disease.  Transpl Int. 2005;  18 651-656
• 111 Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Makuuchi M. Living-related liver transplantation for Wilson's disease.  Clin Transplant. 2005;  19 483-486